SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Results of Operations and Financial Condition

SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) Files An 8-K Results of Operations and Financial Condition

Story continues below


Results of Operations and Financial

On May8, 2017, Sunesis Pharmaceuticals, Inc., or the Company,
reported its financial results for the three months ended
March31, 2017. A copy of the press release issued concerning the
foregoing results is furnished herewith as Exhibit 99.1 and is
incorporated herein by reference.

The press release is furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, or subject to the liabilities of that Section or
Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information contained herein and in the accompanying
exhibit shall not be incorporated by reference into any filing
with the Securities and Exchange Commission made by the Company,
whether made before or after the date hereof, regardless of any
general incorporation language in such filing.

Item9.01. Financial Statements and Exhibits.
(d) Exhibits.




99.1 Press release, dated May8, 2017, entitled Sunesis
Pharmaceuticals Reports First Quarter 2017 Financial Results
and Recent Highlights.


Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.


SUNESIS PHARMACEUTICALS, INC. (NASDAQ:SNSS) closed its last trading session down -0.03 at 3.08 with 331,379 shares trading hands.

An ad to help with our costs